Proteasome inhibitors in cancer therapy: lessons from the first decade.
about
The ubiquitin ligase Itch mediates the antiapoptotic activity of epidermal growth factor by promoting the ubiquitylation and degradation of the truncated C-terminal portion of BidSuppression of the deubiquitinating enzyme USP5 causes the accumulation of unanchored polyubiquitin and the activation of p53The ubiquitin-specific protease USP47 is a novel beta-TRCP interactor regulating cell survivalSpecific small molecule inhibitors of Skp2-mediated p27 degradationDifferential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphomaFunction-oriented biosynthesis of beta-lactone proteasome inhibitors in Salinispora tropicaChemical and biological approaches for adapting proteostasis to ameliorate protein misfolding and aggregation diseases: progress and prognosisBoron chemicals in diagnosis and therapeuticsCharacterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunitIdentification of a β1/β2-specific sulfonamide proteasome ligand by crystallographic screeningLoss of a 20S proteasome activator in Saccharomyces cerevisiae downregulates genes important for genomic integrity, increases DNA damage, and selectively sensitizes cells to agents with diverse mechanisms of actionLargazole and its derivatives selectively inhibit ubiquitin activating enzyme (e1)Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cellsActivation of mutant enzyme function in vivo by proteasome inhibitors and treatments that induce Hsp70Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implicationsThe proteasome inhibitor bortezomib enhances ATRA-induced differentiation of neuroblastoma cells via the JNK mitogen-activated protein kinase pathwayTargeting neuroblastoma stem cells with retinoic acid and proteasome inhibitorInhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737Recognition and processing of ubiquitin-protein conjugates by the proteasomeTargeting Cullin-RING ligases by MLN4924 induces autophagy via modulating the HIF1-REDD1-TSC1-mTORC1-DEPTOR axis.A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies.Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies.Quantitative proteome analysis of the 20S proteasome of apoptotic Jurkat T cells.Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells.Synthesis and biological evaluation of naphthoquinone analogs as a novel class of proteasome inhibitorsHIV protease inhibitors block oral epithelial cell DNA synthesis.Effects of a novel proteasome inhibitor BU-32 on multiple myeloma cells.Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.Inhibition of Neddylation Modification Sensitizes Pancreatic Cancer Cells to Gemcitabine.Forkhead box M1 transcription factor: a novel target for cancer therapy.Oxidative stress by targeted agents promotes cytotoxicity in hematologic malignancies.Aggresome formation is regulated by RanBPM through an interaction with HDAC6An atlas of altered expression of deubiquitinating enzymes in human cancerCombination of bortezomib and daunorubicin in the induction of apoptosis in T-cell acute lymphoblastic leukemiaGenerating a generation of proteasome inhibitors: from microbial fermentation to total synthesis of salinosporamide a (marizomib) and other salinosporamidesBortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathwaysUbiquitin/proteasome pathway impairment in neurodegeneration: therapeutic implicationsAcylpeptide hydrolase inhibition as targeted strategy to induce proteasomal down-regulation.Small interfering RNA targeting mcl-1 enhances proteasome inhibitor-induced apoptosis in various solid malignant tumorsSalinosporamide natural products: Potent 20 S proteasome inhibitors as promising cancer chemotherapeutics.
P2860
Q24306628-0029BF9F-3A59-4530-98AE-78DFC919F60AQ24309310-03470AF6-D5DF-4098-A513-9BC945039830Q24336640-F6763396-C2E9-47DA-A8AF-78DB3373FF4CQ24596988-145A1E56-73FB-4353-AAAD-4FEB0371B4E9Q24643447-1995E418-50F2-4686-ACAE-275A7EFBF060Q24646019-BE34D2A8-212C-49CE-8190-AC99F8FE1527Q27004511-8CF8DF14-9C91-4061-B960-70BB3AB3BC98Q27006075-850F701E-2072-463D-8459-A31255815B40Q27663486-10B8BFBE-1E27-4A18-BD8D-0C91F41E0CF4Q27701726-99487F7F-42AA-499A-80A8-68C6182FA075Q27930325-9AA7AE20-830A-433D-9314-E11606786A88Q28258201-F209E72C-E91A-4B9D-B3D3-0826A65CFDC1Q28279454-5E2FAED4-87F3-4E7D-BA7C-363EF40EC24AQ28472376-B51CA450-41DD-4113-9F9A-F085444131D1Q28474843-182ED523-71E9-4D90-8032-46744549799AQ28477838-615F9563-9994-472F-9D65-FEA0329C0FA2Q28534151-52C333DC-F3BD-485F-8644-BD36FD509302Q28542684-9042BF18-2CB7-4F01-B239-4592923F3F54Q29547616-C7A614FC-CE7E-40DB-A26C-0EC6E7563241Q30525356-AE7D0E49-D80D-4075-A2E1-04EE2560EF6DQ33387006-85E216FB-E4E2-49C6-81F3-9BC189397764Q33421241-37C51B1D-C230-4C16-8383-6339A1E20856Q33549232-553053E5-BA3F-46E1-AC63-8A5CA3810FA1Q33584749-D8478304-4042-453B-8F1B-1655B4DE9EC2Q33629972-3C09F200-2B02-4221-82E2-01F45F6AE32CQ33639842-E09AA1E1-CC3F-4694-A198-2303B18CA9A6Q33675494-DC12DBDF-38B6-4EA4-8504-EC5D441D6D44Q33691759-64EBD6E1-0BA5-4CA5-9089-435A851E7902Q33714709-D5907089-77B8-4989-A9E8-AE6B3065F75FQ33729250-35CE2842-F2B8-4894-98B9-2D9F38527346Q33741142-B515EDCF-DADE-4B9F-8610-F11FFEE11CAAQ33757230-E29F5E2B-6416-4FFF-8F03-F70125BE848BQ33808690-95D04DA9-3BDC-4CEF-8BA4-244A8C49FFCFQ33828073-57FC9294-8647-4A20-988D-5E03DD00CBBDQ33836952-082BBC92-ED37-4857-BFF5-502D5FC6D00BQ33907593-20FD9B0F-22BC-4485-B5D9-CF94244DA1F1Q34012297-3D2394F3-2A6C-4A46-A0AD-D71561DB123DQ34053359-EAC396E4-BBC7-4411-83DB-5C63BCE8D686Q34073160-439C1360-F526-4732-B777-BD36AAC6C263Q34142223-7C7AD839-226C-4B92-9D0D-DC74E5D7DCDB
P2860
Proteasome inhibitors in cancer therapy: lessons from the first decade.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Proteasome inhibitors in cancer therapy: lessons from the first decade.
@en
Proteasome inhibitors in cancer therapy: lessons from the first decade.
@nl
type
label
Proteasome inhibitors in cancer therapy: lessons from the first decade.
@en
Proteasome inhibitors in cancer therapy: lessons from the first decade.
@nl
prefLabel
Proteasome inhibitors in cancer therapy: lessons from the first decade.
@en
Proteasome inhibitors in cancer therapy: lessons from the first decade.
@nl
P1476
Proteasome inhibitors in cancer therapy: lessons from the first decade.
@en
P2093
Deborah J Kuhn
P304
P356
10.1158/1078-0432.CCR-07-2218
P407
P577
2008-03-01T00:00:00Z